First patient enrolled for all cohorts of
First data from
Retained benefit analysis from Phase 2 portion of CARDINAL expected 3Q18
The Phase 2 PHOENIX program is studying bardoxolone in patients with autosomal dominant polycystic kidney disease (“ADPKD”), IgA nephropathy, focal segmental glomerulosclerosis (“FSGS”), and CKD associated with type 1 diabetes. Approximately 25 patients per cohort will receive bardoxolone open-label, orally, once-daily for 12 weeks. The purpose of this study is to determine the safety and efficacy of bardoxolone, and the primary efficacy endpoint is change from baseline in eGFR after 12 weeks of treatment. Each cohort of patients is being independently enrolled and analyzed, and each has now enrolled at least one patient. The Company anticipates that initial data from one or more
CARDINAL is a Phase 2/3 study of bardoxolone in patients with CKD caused by Alport syndrome. The Phase 2 portion of CARDINAL enrolled a total of 30 patients to assess the safety and efficacy of once-daily, oral administration of bardoxolone, and its primary efficacy endpoint was change from baseline in estimated glomerular filtration rate (eGFR) at week 12. Full primary endpoint results from the study were reported in
Results from the 52-week retained benefit analysis are relevant to the ongoing Phase 3 portion of CARDINAL, a double-blind, placebo-controlled trial enrolling up to 150 patients worldwide. This Phase 3 study can support accelerated approval by the
“Diverse forms of CKD are driven by a common final set of inflammatory pathways that bardoxolone targets,” said
About Bardoxolone Methyl
Bardoxolone methyl is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. In addition to CARDINAL and
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (iv) other factors set forth in Reata’s filings with the
Vice President, Strategy
Matt Middleman, M.D.
LifeSci Public Relations
Source: Reata Pharmaceuticals, Inc.